Fulcrum Therapeutics
FULC
169 hedge funds and large institutions have $550M invested in Fulcrum Therapeutics in 2026 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 74 increasing their positions, 38 reducing their positions, and 38 closing their positions.
446% more call options, than puts
Call options by funds: $7.41M | Put options by funds: $1.36M
95% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 38
3% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 38
2% less funds holding
Funds holding: 172 → 169 (-3)
16.94% less ownership
Funds ownership: 124.62% → 107.68% (-17%)
28% less capital invested
Capital invested by funds: $763M → $550M (-$213M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$12.3M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$11.1M |
| 3 |
BlackRock
New York
|
+$10.5M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$8.89M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$12.1M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$11.5M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$10.4M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.05M |
| 5 |
SCM
Sio Capital Management
New York
|
-$4.32M |
FULC Hedge Fund Activity: Q1 2026 in Review
169 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q1 2026, worth a combined $550M — down 28% from $763M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of FULC and 37 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 74 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $12.3M. The largest seller was Adage Capital Partners, cutting an estimated $12.1M.
- 169 institutional investors held Fulcrum Therapeutics (FULC) as of Q1 2026, down from 172 in Q4 2025.
- Funds reported $550M of Fulcrum Therapeutics stock for Q1 2026, down 28% quarter-over-quarter.
- 37 funds opened new Fulcrum Therapeutics positions in Q1 2026 and 38 closed out, a net change of -1 holder.
- The largest Fulcrum Therapeutics buyer in Q1 2026 was Alyeska Investment Group, an estimated $12.3M added.
- The largest Fulcrum Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $12.1M sold.
Based on aggregated 13F filings for Q1 2026.